[Pubmed] On the road to blood biomarkers in myasthenia gravis (MG): Beyond clinical scales

[RSS-Bot]

J Neuromuscul Dis. 2025 Jun 25:22143602251348753. doi: 10.1177/22143602251348753. Online ahead of print.

ABSTRACT

Myasthenia Gravis (MG) is a heterogeneous neuromuscular autoimmune disorder characterized by fluctuating skeletal muscle weakness and a highly variable disease course. MG subgroups are defined by antibody type, age at onset, clinical phenotype, and thymus pathology. Given the unpredictable disease course, disease-specific objective biomarkers are needed to enable personalized treatment strategies and improve clinical trial outcomes beyond conventional clinical scales. Biomarkers are measurable indicators of physiological processes, disease states, and therapy responses. Despite significant advances in MG diagnostics and therapeutics, predictive biomarkers for personalized treatment remain underdeveloped. This review explores the progress and challenges in identifying blood-based biomarkers for MG, highlighting their potential applications in diagnosis and disease monitoring. Established diagnostic blood biomarkers include autoantibodies against acetylcholine receptors (AChR) and muscle-specific tyrosine kinase (MuSK), which confirm MG diagnosis and guide initial treatment decisions. Prognostic biomarkers, such as microRNAs (miR-150-5p and miR-30e-5p), show promise in predicting disease progression. Pharmacodynamic biomarkers, including CD20+ B cell counts, may enhance treatment precision for therapies like Rituximab. Furthermore, emerging research on metabolites, T and B-cell markers, complement factors, and proteomics offer new avenues to refine MG subtyping and identify molecular signatures predictive of treatment response to novel immunosuppressants. While the journey toward clinically useful blood biomarkers in MG remains complex, ongoing collaborative efforts within the MG research community hold the potential to revolutionize disease management. Future studies integrating multi-omics approaches, large-scale longitudinal cohorts, and disease controls will be critical to translating these biomarkers from research into routine clinical practice.

PMID:40560146 | DOI:10.1177/22143602251348753


Source: https://pubmed.ncbi.nlm.nih.gov/4056014 ... t9+e462414